Clinical features of long-term survivors of recurrent epithelial ovarian cancer

International Journal of Clinical Oncology

Volumn 20, Issue 1, 2015, Pages 143-149

  Iwase, Haruko ^a,b   Takada, Toshio ^a   Iitsuka, Chiaki ^a   Nomura, Hidetaka ^a   Abe, Akiko ^a   Taniguchi, Tomoko ^a   Sakamoto, Kimihiko ^a   Takizawa, Ken ^a   Takeshima, Nobuhiro ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Disease free interval; Long term survival; Platinum sensitivity; Recurrent epithelial ovarian cancer

Indexed keywords

PLATINUM COMPLEX;

ADULT; AGED; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896432778     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0687-1     Document Type: Article

References (25)

1. Japan Society of Gynecologic Oncology (2010) Ovarian cancer treatment guidelines 2010. Kanehara & Co., Ltd., Tokyo
2. Heinz APM, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO sixth annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192
3. du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinscaht Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVER) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244
4. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382
5. Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393
6. Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–211
7. Blackledge G, Lawton F, Redman C et al (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653
8. Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer–treatment of recurrent disease. Lancet Oncol 3:537–545
9. Santillan A, Karam AK, Li AJ et al (2007) Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 104:686–690
10. Gadducci A, Cosio S, Zola P et al (2010) The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecol Oncol 116:358–363
11. Salani R, Santillan A, Zahurak ML et al (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Analysis of prognostic factors and survival outcome. Cancer 109:685–691
12. Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032
13. Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939
14. Eisenkop SM, Fridedman RL, Wang HJ (1995) Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76:1606–1614
15. Zang RY, Zhang ZY, Li ZT et al (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75:24–30
16. Eisenkop SM, Fridedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancer. Cancer 88:144–153
17. Bristow RE, Gossett DR, Shook DR et al (2002) Recurrent micropapillary serous ovarian carcinoma. Cancer 95:791–800
18. Wagner U, Marth C, Largiller R et al (2012) Final survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591
19. Aghajanian C, Blank SV, Goff A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045
20. Mutch DG, Orland M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811–2818
21. Vergote I, Finkler N, del Campo J et al (2009) Phase 3 randomized study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324–2332
22. Kajiyama H, Shibata K, Mizuno M et al (2012) Long-term clinical outcome of patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 22:394–399
23. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707
24. Ferrero JM, Weber B, Geay JF et al (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18:263–268
25. Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynäekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710